Audit: QRS - Biotin for Health & Longevity

Audit conducted on 22/09/2026 16:30 using AI4L / Opus 5

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) × 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every span traced to an ER passage: protocol cells to ER lines 326/328/334, gates to lines 280-300, tiers to lines 154-262, monitoring table to lines 405-421.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No established target” (marker_2_target) and “No clinically meaningful interaction documented” (caution_items) carry the ER’s hedges verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindications stay absolute; “Caution”/”Monitor” tags on interactions match the ER’s own words.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All gate items come from `Key Interactions & Contraindications`; tiers come from the matching ER tier headings only.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs or expert names in the QRS; the named drugs (carbamazepine, glipizide, etc.) appear in the ER for the same bullets.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Lede mirrors the ER `Conclusion` register closely.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells state regimens as facts, not instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or directive constructions outside the template disclaimer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of should/recommend/advise/must in document content.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained only where the ER’s biomarker and interaction names require them.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for you/your/we/our.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Monitoring table and washout cadence assume a self-tracking reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	72-hour washout and research-grade urinary marker retained without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Assay interference is surfaced as the dominant consideration, which is the ER’s own reading for a frequently-tested reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Title uses “Health & Longevity”; no “anti-aging” anywhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No lay route-of-administration or lay adverse-event wording; clinical register retained throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings byte-identical to the template.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	34 fixed spans plus the repeated marker_#/qualitative_item_# sets expanded to 7 markers and 5 qualitative items; none missing.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows changes only inside addressed spans plus the sanctioned display:none wrappers.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section surfaced by the QRS is empty; the empty Medium-risk tier is governed by 13.5, which mandates display:none instead of empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Supplemental cosmetic dosing”, “Best time of day”, “Brittle-nail protocol”, “Time to effect”, “Raw egg white (avidin)”, “Chromium picolinate” all verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s tier squares and ⚠️ markers were dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Gate items reduced to key facts; monitoring “why” cells one line each.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2-14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” line 3, closing line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only `duration: "00:02"` is quoted, which the colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	`er_filename: biotin_2026-0907-0002_Opus_ER.md`
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	`qrs_prompt_version: 26.9.22` matches this prompt.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	`qrs_creation_date: 2026-0922-1616`
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	`Opus`
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	`Opus 5`, no qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	“Biotin for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	“Biotin for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0922-1616 → 09/22/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the template’s title and subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Biotin is a vitamin sold in large doses as a supplement for hair, skin, and nails.”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Compresses all four Conclusion paragraphs into the deficiency case, the evidence ranking, and the assay-interference trade-off.
7.3	[at_a_glance] is no longer than 70 words	🟢	Exactly 70 words (counted programmatically).
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Mapped to ER lines 441, 443 and 445.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“make new sugar”, “blood-fat findings”, “automated blood tests” — no acronyms.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All seven items trace to ER lines 290-300.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Both absolute bullets plus all five “Populations who should avoid Biotin” entries are present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven `<li>` elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic tails (“Avidin binds biotin irreversibly…”, “in whom delayed clearance prolongs…”) all stripped; no dash-trailing clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	≥10 mg/day, 72 hours, ≥5 mg/day, 300 µg/day and eGFR <30 mL/min/1.73 m² all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names such populations and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All five items trace to ER lines 280-288.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The two absolute bullets (raw egg white, biotin-based diagnostics) correctly appear only in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Five `<li>` elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Transport/catabolism rationale and the ER’s parenthetical gloss on sulfonylureas are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Antiseizure and antibiotic drug lists carried verbatim; the OTC classes retained in shortened form.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names five such interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	All three cells trace to ER `Therapeutic Protocol` lines 326, 328 and 334.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Everyday dose range, dosing time relative to the washout, and the only evidenced nail regimen.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER’s Protocol section lists twelve aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	Nine spans populated, each mapping to ER Protocol text.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER supplies only two distinct aspects (MS walking speed at 12-15 months; nail/hair change at 3-6 months); both are used.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	High-tier MS walking speed first, Low-tier nail/hair second.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	Third pcell carries style=”display: none” with all three spans empty and an HTML comment recording the basis.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Six spans populated from ER lines 166 and 377.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	The ER does provide time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	All nine benefits map one-to-one to the ER’s tier headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Heading-level phrases only; magnitudes and the ER’s “Net reading” sentences omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	All five risks map to the ER’s tier headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The 4.7% interference frequency and the 0.2-7.4% population range are omitted, as required.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	[risks_medium] carries style=”display: none” with an HTML comment quoting the ER’s “No risk reaches Medium”.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	Rows mirror the ER biomarker table at lines 405-413.
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All seven ER biomarkers present, with targets and “why” text carried across.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	“Baseline while biotin-free, repeat at 12 weeks, then every 6-12 months, always after a 72-hour washout” from ER line 403.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	Taken from the ER’s “Qualitative markers worth tracking” list, lines 417-421.
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	All five ER qualitative markers present and unabridged.

Issues 22/09/2026 16:30

Pass rate 100.00%. No issues found.

Issues 22/09/2026 16:27

1.3 — Interference hedge dropped: [at_a_glance] (line 433) states that concentrated doses “distort most automated blood tests”, strengthening the ER Conclusion (line 445), which says biotin binds the pair “most automated blood tests rely on” and “can push results in either direction”.

Fixes 22/09/2026 16:27

1.3 — Interference hedge restored: Changed [at_a_glance] from “concentrated doses distort most automated blood tests” to “concentrated doses can distort most automated blood tests”, matching the ER Conclusion’s “can push results in either direction”; the section remains within the 70-word limit.

Issues 22/09/2026 16:22

11.2 — Time-to-effect sets misordered: time_1 holds the hair/nail horizon (ER benefit tier “Low”) while time_2 holds the progressive-multiple-sclerosis walking-speed timepoint (ER benefit tier “High”), so the sets are not ordered by the magnitude of the related benefit.

Fixes 22/09/2026 16:22

11.2 — Time-to-effect sets reordered: Swapped the two populated time-to-effect cells so time_1 now carries the progressive-multiple-sclerosis walking-speed horizon (12–15 months, ER benefit tier “High”) and time_2 carries the hair/nail horizon (3–6 months, ER benefit tier “Low”), putting the sets in order of the magnitude of the related benefit.